XNAS · BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) · BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Includes notes from domestic 8-K and foreign private issuer 6-K disclosures.
TL;DR: Biogen reported Q1 2026 revenue of $2.478B, up 1.9% from $2.431B a year ago, with GAAP diluted EPS of $2.15 and net income of $319.5M.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 6/9/2026 | Freire Maria C | — | GRANT | 2,005 | — | — |
| 6/9/2026 | Minor Lloyd | — | GRANT | 1,505 | — | — |
| 6/9/2026 | Pangalos Menelas N | — | OPTION_EXERCISE | -2,370 | — | — |
| 6/9/2026 | Pangalos Menelas N | — | GRANT | 1,505 | — | — |
| 6/9/2026 | Pangalos Menelas N | — | OPTION_EXERCISE | 2,370 | — | — |
| 6/9/2026 | Patolawala Monish D | — | GRANT | 1,505 | — | — |
| 6/9/2026 | LANGER SUSAN | — | GRANT | 1,505 | — | — |
| 6/9/2026 | Mantas Jesus B | — | GRANT | 1,505 | — | — |
| 6/9/2026 | Rowinsky Eric K | — | GRANT | 1,505 | — | — |
| 6/9/2026 | SHERWIN STEPHEN A | — | GRANT | 1,505 | — | — |
| 6/9/2026 | HAWKINS WILLIAM A | — | GRANT | 1,505 | — | — |
| 5/1/2026 | Keeney Adam | Head of Corporate Development | OPTION_EXERCISE | 939 | — | — |
| 5/1/2026 | Keeney Adam | Head of Corporate Development | TAX_WITHHOLD | -455 | $187 | $85,112 |
| 5/1/2026 | Keeney Adam | Head of Corporate Development | OPTION_EXERCISE | -939 | — | — |
| 4/1/2026 | Godbout Sean | Chief Accounting Officer | OPTION_EXERCISE | 181 | — | — |
| 4/1/2026 | Godbout Sean | Chief Accounting Officer | TAX_WITHHOLD | -54 | $184 | $9,924 |
| 4/1/2026 | Godbout Sean | Chief Accounting Officer | OPTION_EXERCISE | -181 | — | — |
| 2/13/2026 | Viehbacher Christopher | President and CEO | GRANT | 38,015 | — | — |
| 2/13/2026 | Singhal Priya | Head of Development | GRANT | 10,560 | — | — |
| 2/13/2026 | Murphy Nicole | Head of Pharm Ops and Tech | GRANT | 10,560 | — | — |